AKTX
NASDAQAkari Therapeutics PLC
$18.27
+13.13 (+255.45%)
2026-05-22 00:00
Healthcare
Biotechnology
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$4.2M
P/E Ratio
N/A
52W Low
52W High
$0.12
$18.99
Volume
31.8M
Analyst Rating
Hold
Target: $62
9 Analyst Ratings
Strong Buy
0
Buy
0
Hold
9
Sell
0
Price Target Range
Low: $5
Avg: $62
High: $153
About Akari Therapeutics PLC
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, ...
Employees
5
Website
akaritx.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | N/A | N/A% | -$17.3M | -$10.6M |
| 2024 | N/A | N/A% | -$19.8M | -$12.6M |
| 2023 | N/A | N/A% | -$10.0M | -$16.4M |
| 2022 | N/A | N/A% | -$17.7M | -$21.5M |
| 2021 | N/A | N/A% | -$17.4M | -$18.8M |
| 2025 Q4 | N/A | N/A% | -$5.3M | -$3.0M |
| 2025 Q3 | N/A | N/A% | -$6.4M | -$2.1M |
| 2025 Q2 | N/A | N/A% | -$1.9M | -$3.3M |
| 2025 Q1 | $26K | -13558.7% | -$3.7M | -$2.1M |
| 2024 Q4 | N/A | N/A% | -$3.8M | -$2.1M |
| 2024 Q3 | N/A | N/A% | -$2.9M | -$1.5M |
| 2024 Q2 | N/A | N/A% | -$7.6M | -$4.9M |
| 2024 Q1 | N/A | N/A% | -$5.6M | -$4.0M |